ISONIAZID TREATMENT FOR TUBERCULIN REACTORS

THE EFFECTIVENESS of isoniazid in preventing the extrapulmonary complications of primary tuberculosis in infants and young children has now been established. Considering the severely damaging and often fatal forms the complications can take, such as meningitis and skeletal tuberculosis, this treatme...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 1961-02, Vol.27 (2), p.179-180
Main Author: COMMITTEE OF SECTION ON DISEASES OF THE CHEST
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c167t-2befc4bdbd83669bd06f729d105b6cc6a9ff86ff4783bcfc24a6321cc10833553
cites
container_end_page 180
container_issue 2
container_start_page 179
container_title Pediatrics (Evanston)
container_volume 27
creator COMMITTEE OF SECTION ON DISEASES OF THE CHEST
description THE EFFECTIVENESS of isoniazid in preventing the extrapulmonary complications of primary tuberculosis in infants and young children has now been established. Considering the severely damaging and often fatal forms the complications can take, such as meningitis and skeletal tuberculosis, this treatment is indeed a welcomed discovery. The large control study by the Public Health Service that established the efficacy of this treatment was developed at the urging of pediatricians who had observed that children whose tuberculosis was treated with isoniazid did not develop meningitis or other sequelae. Through the participation of 33 pediatric clinics throughout the United States, 2,750 children with asymptomatic primary tuberculosis were entered in the study. The principal criterion for selecting children for the study was a reaction to the intermediate dose (5 TU) of tuberculin of induration in diameter of at least 5 mm. Children, 3 years of age or older, had in addition, roentgenographic evidence of primary tuberculosis.
doi_str_mv 10.1542/peds.27.2.179
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1542_peds_27_2_179</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1542_peds_27_2_179</sourcerecordid><originalsourceid>FETCH-LOGICAL-c167t-2befc4bdbd83669bd06f729d105b6cc6a9ff86ff4783bcfc24a6321cc10833553</originalsourceid><addsrcrecordid>eNotz79LxDAYxvEgHljPG927S-qbN7_asdaeFmoLvXRxCU3agKJ4NC7-996h0wPf4YEPIbcMMiYF3h-XOWaoM8yYLi5IwqDIqUAtL0kCwBkVAPKKXMf4DgBCakzIXXPou6Z8bR5TM9Sleak7k-77ITXjQz1UY9t06alXph8ON2QTpo-47P53S8Z9bapn2vZPTVW21DOlvym6JXjhZjfnXKnCzaCCxmJmIJ3yXk1FCLkKQeicOx88iklxZN4zyDmXkm8J_fv161eM6xLscX37nNYfy8CepfYstagt2pOU_wIp1UM0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>ISONIAZID TREATMENT FOR TUBERCULIN REACTORS</title><source>EZB Electronic Journals Library</source><creator>COMMITTEE OF SECTION ON DISEASES OF THE CHEST</creator><creatorcontrib>COMMITTEE OF SECTION ON DISEASES OF THE CHEST</creatorcontrib><description>THE EFFECTIVENESS of isoniazid in preventing the extrapulmonary complications of primary tuberculosis in infants and young children has now been established. Considering the severely damaging and often fatal forms the complications can take, such as meningitis and skeletal tuberculosis, this treatment is indeed a welcomed discovery. The large control study by the Public Health Service that established the efficacy of this treatment was developed at the urging of pediatricians who had observed that children whose tuberculosis was treated with isoniazid did not develop meningitis or other sequelae. Through the participation of 33 pediatric clinics throughout the United States, 2,750 children with asymptomatic primary tuberculosis were entered in the study. The principal criterion for selecting children for the study was a reaction to the intermediate dose (5 TU) of tuberculin of induration in diameter of at least 5 mm. Children, 3 years of age or older, had in addition, roentgenographic evidence of primary tuberculosis.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.27.2.179</identifier><language>eng</language><ispartof>Pediatrics (Evanston), 1961-02, Vol.27 (2), p.179-180</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c167t-2befc4bdbd83669bd06f729d105b6cc6a9ff86ff4783bcfc24a6321cc10833553</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>COMMITTEE OF SECTION ON DISEASES OF THE CHEST</creatorcontrib><title>ISONIAZID TREATMENT FOR TUBERCULIN REACTORS</title><title>Pediatrics (Evanston)</title><description>THE EFFECTIVENESS of isoniazid in preventing the extrapulmonary complications of primary tuberculosis in infants and young children has now been established. Considering the severely damaging and often fatal forms the complications can take, such as meningitis and skeletal tuberculosis, this treatment is indeed a welcomed discovery. The large control study by the Public Health Service that established the efficacy of this treatment was developed at the urging of pediatricians who had observed that children whose tuberculosis was treated with isoniazid did not develop meningitis or other sequelae. Through the participation of 33 pediatric clinics throughout the United States, 2,750 children with asymptomatic primary tuberculosis were entered in the study. The principal criterion for selecting children for the study was a reaction to the intermediate dose (5 TU) of tuberculin of induration in diameter of at least 5 mm. Children, 3 years of age or older, had in addition, roentgenographic evidence of primary tuberculosis.</description><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1961</creationdate><recordtype>article</recordtype><recordid>eNotz79LxDAYxvEgHljPG927S-qbN7_asdaeFmoLvXRxCU3agKJ4NC7-996h0wPf4YEPIbcMMiYF3h-XOWaoM8yYLi5IwqDIqUAtL0kCwBkVAPKKXMf4DgBCakzIXXPou6Z8bR5TM9Sleak7k-77ITXjQz1UY9t06alXph8ON2QTpo-47P53S8Z9bapn2vZPTVW21DOlvym6JXjhZjfnXKnCzaCCxmJmIJ3yXk1FCLkKQeicOx88iklxZN4zyDmXkm8J_fv161eM6xLscX37nNYfy8CepfYstagt2pOU_wIp1UM0</recordid><startdate>19610201</startdate><enddate>19610201</enddate><creator>COMMITTEE OF SECTION ON DISEASES OF THE CHEST</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19610201</creationdate><title>ISONIAZID TREATMENT FOR TUBERCULIN REACTORS</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c167t-2befc4bdbd83669bd06f729d105b6cc6a9ff86ff4783bcfc24a6321cc10833553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1961</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>COMMITTEE OF SECTION ON DISEASES OF THE CHEST</creatorcontrib><collection>CrossRef</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><aucorp>COMMITTEE OF SECTION ON DISEASES OF THE CHEST</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ISONIAZID TREATMENT FOR TUBERCULIN REACTORS</atitle><jtitle>Pediatrics (Evanston)</jtitle><date>1961-02-01</date><risdate>1961</risdate><volume>27</volume><issue>2</issue><spage>179</spage><epage>180</epage><pages>179-180</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><abstract>THE EFFECTIVENESS of isoniazid in preventing the extrapulmonary complications of primary tuberculosis in infants and young children has now been established. Considering the severely damaging and often fatal forms the complications can take, such as meningitis and skeletal tuberculosis, this treatment is indeed a welcomed discovery. The large control study by the Public Health Service that established the efficacy of this treatment was developed at the urging of pediatricians who had observed that children whose tuberculosis was treated with isoniazid did not develop meningitis or other sequelae. Through the participation of 33 pediatric clinics throughout the United States, 2,750 children with asymptomatic primary tuberculosis were entered in the study. The principal criterion for selecting children for the study was a reaction to the intermediate dose (5 TU) of tuberculin of induration in diameter of at least 5 mm. Children, 3 years of age or older, had in addition, roentgenographic evidence of primary tuberculosis.</abstract><doi>10.1542/peds.27.2.179</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 1961-02, Vol.27 (2), p.179-180
issn 0031-4005
1098-4275
language eng
recordid cdi_crossref_primary_10_1542_peds_27_2_179
source EZB Electronic Journals Library
title ISONIAZID TREATMENT FOR TUBERCULIN REACTORS
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T09%3A07%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ISONIAZID%20TREATMENT%20FOR%20TUBERCULIN%20REACTORS&rft.jtitle=Pediatrics%20(Evanston)&rft.aucorp=COMMITTEE%20OF%20SECTION%20ON%20DISEASES%20OF%20THE%20CHEST&rft.date=1961-02-01&rft.volume=27&rft.issue=2&rft.spage=179&rft.epage=180&rft.pages=179-180&rft.issn=0031-4005&rft.eissn=1098-4275&rft_id=info:doi/10.1542/peds.27.2.179&rft_dat=%3Ccrossref%3E10_1542_peds_27_2_179%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c167t-2befc4bdbd83669bd06f729d105b6cc6a9ff86ff4783bcfc24a6321cc10833553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true